ALK-Activating Homologous Mutations in LTK Induce Cellular Transformation

J. Devon Roll(Moffitt Cancer Center), Gary W. Reuther(Moffitt Cancer Center)

PLoS ONE

February 9, 2012

10.1371/journal.pone.0031733

Cited by 39

Related Papers

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells

|Oncotarget|2015|38

Activation of JAK2-V617F by Components of Heterodimeric Cytokine Receptors

|Journal of Biological Chemistry|2010|30

<scp>SHP2</scp> inhibition displays efficacy as a monotherapy and in combination with <scp>JAK2</scp> inhibition in preclinical models of myeloproliferative neoplasms

|American Journal of Hematology|2024|4